Nutraceuticals is another area where the company is expanding its operations, catering to cardiac, diabetic and kidney disease patients, Saxena added.
The Mumbai-headquartered firm is also adopting two pronged strategy for growth as the company is targeting to establish leadership for its various in-licensed products and at the same time also trying to develop its own brand portfolio in the country.
"Elder's focus is on creating a product in a therapeutic category and to try to establish brand leadership in that segment, apart from developing our own portfolio," Saxena said.
Last week, the drug firm's shareholders approved a final dividend of 30 per cent or Rs 3 per share of face value of Rs 10 each for the fiscal ended March 31, 2012.
No comments:
Post a Comment
Please feel free to contact or comment the article